Compare UTL & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTL | OPK |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.9M | 921.2M |
| IPO Year | 1995 | 2011 |
| Metric | UTL | OPK |
|---|---|---|
| Price | $50.73 | $1.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $56.50 | $1.60 |
| AVG Volume (30 Days) | 82.6K | ★ 2.1M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 1.37 | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | $536,000,000.00 | ★ $606,879,000.00 |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | $4.22 | $4.24 |
| P/E Ratio | $27.40 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $45.11 | $0.98 |
| 52 Week High | $55.34 | $1.60 |
| Indicator | UTL | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 43.67 |
| Support Level | $49.14 | $1.12 |
| Resistance Level | $53.33 | $1.25 |
| Average True Range (ATR) | 1.43 | 0.04 |
| MACD | -0.27 | -0.01 |
| Stochastic Oscillator | 37.91 | 55.85 |
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.